Navigation Links
Hard To Treat Diseases (HTDS.PK) IP Rights Pink Sheets Filings
Date:8/26/2009

SHENZHEN, China, Aug. 26 /PRNewswire-FirstCall/ - Hard to Treat Diseases (the "Company") (HTDS.PK) www.htdsmedical.com provides access to U.S. Patent and Trademark Office.("USPTO") documents relating to intellectual property ("IP") ownership rights of the Company.

HTDS management has duly notified the OTCBB company utilizing the IP rights of the Company and is providing its shareholders with certain other "Supplementary" filings made yesterday with Pink Sheets. The information can be accessed at http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds

The supplementary filings made on Pink Sheets by HTDS include the actual copies of the USPTO recording documents, the letter to the OTCBB Company utilizing HTDS rights and proof of FedEx delivery of the same.

These documents are self explanatory.

HTDS management is of the opinion that this information is material, and both issuers need to disclose its potential effect to its shareholders and investors. The OTCBB company is in default in their filings with the SEC. and has received an "e" on its symbol as a late filing issuer.

HTDS ownership rights for the five patents can be accessed at the following five USPTO websites:

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=5223543 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=6743828 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=7241858 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=7321003 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=7476696 pub= asnr= asnri= asne= asnei= asns=

HTDS management will continue to monitor the situation and intends to vigorously escalate its claim to protect its interests. The Company is not ruling out any available options at this point regarding the IP rights that may have a positive significant impact on the entire value of HTDS.

Further updates to follow.

Safe Harbor Statement:

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Berry Truth: Cystex Know Your Bladder Better Video Explains Why Cranberries Are Great for UTI Prevention, But Not for Treatment
2. Experimental Treatment Could Fight Muscular Dystrophy
3. Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
4. Surgical treatment a rare complication of duodenal diverticulum
5. Introducing anuleaf AD, a New FDA-Approved Hemorrhoid Treatment
6. Treating Prostate Cancer: Old School vs. New School
7. Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
8. EndyMed Medical Receives FDA Clearance for Painless, Non-invasive Anti-Wrinkle Treatment System
9. New treatments offer better survival and fresh challenges in colorectal cancer
10. Study finds low risk in treating previously coiled aneurysm
11. Night home hemodialysis shown to be as good as transplant in treating kidney failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... to family wealth and to housing, with more advantaged communities providing richer opportunities. ... five types of interventions: (a) school improvement policies; (b) school choice policies; (c) ...
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed by ongoing ... therapy technology, protocols and patient results as have been achieved with Okyanos Cell ... accessible standard of care for patients worldwide. , As the Medical Advisory Chairman at ...
(Date:5/24/2016)... ... , ... Backed by decades of experience, Metroloji Okulu works ... best suited solution to meet regulatory requirements. Their professional staff also performs on-site ... , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical data ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, ... in the development of technological innovations that lead to broad-based healthcare solutions. , ...
(Date:5/24/2016)... ... , ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on May ... the world who do not have access to a toilet, even when they’re on their ... of #perioddrama. The (sometimes hilarious) results help shine a light on the awkwardness that women ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 /PRNewswire/ ... primer stent de doble terapia del mundo, introduce ... fístula arteriovenosa. OrbusNeich, una compañía global ... cambian las vidas, ha expandido su cartera incluyendo ... catéteres balón JADE™ y Scoreflex™ PTA son los ...
(Date:5/24/2016)... Een app die artsen over ... patiënten kunnen behandelen, hun kennis kunnen delen en van ... nieuwe en revolutionaire MDLinking App, ontwikkeld door een internationale ... Hans Flu en oncologisch chirurg dr. Gijs van ... wordt op dinsdag 24 mei officieel gepresenteerd op het ...
Breaking Medicine Technology: